Chronic active Epstein-Barr exacerbated by COVID-19 co-infection

Villafuerte, David; Lavrynenko, Olga; Qazi, Rayan; Passeri, Marco F.; Sanchez, Fernando L.

doi:10.1016/j.ijid.2022.07.046

Cited by 5 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dinesh Verma, et al stated that EBV infection affects the efficiency and severity of SARS-CoV-2 infection by increasing the expression of ACE2, the cellular receptor for SARS-CoV-2, on epithelial cells [20]. Six EBV/SARS-CoV-2 co-infection cases [11,[21][22][23][24][25] have so far been reported globally. These cases however did not particularly suggest any increased risk of COVID-19 in EBV-infected patients.…”

Section: Discussionmentioning

confidence: 99%

Chronic active Epstein-Barr virus infection with reinfection of SARS-CoV-2: a case report

Wu,

Liu,

et al. 2024

Virol J

View full text Add to dashboard Cite

We describe the case of a 57-year-old male with jaundice, abdominal distension and fatigue. He was diagnosed as chronic active Epstein-Barr virus infection (CAEBV) due to intermittent elevated liver enzymes, hepatosplenomegaly and pancytopenia, with persistent positive of EBV biomarkers in blood and also positive in liver tissue. The patient was reinfected by SARS-CoV-2 within 2 months companied with CAEBV. The patient’s second infection with SARS-CoV-2 led to the aggravated liver dysfunction with pneumonia and re-admission. After receiving symptomatic treatment, the patient showed significantly improvement of symptoms with partially restoration of liver function. After discharge, the patient’s health status continued to deteriorate and eventually died. The instances of SARS-CoV-2 co-infection with the original chronic virus are not uncommon, but the exact mechanism of EBV and SARS-CoV-2 coinfection and the relationship between them are still unclear. Since co-infection of SARS-CoV-2 with original chronic virus might affect each other and lead disease aggravated and complicated, it is necessary to differentiate in the diagnosis of disease and it is important to be aware of the re-infection signs of SARS-CoV-2 in people with chronic virus infection diseases, as well as the risk of co-infection of SARS-CoV-2 with other viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

Chronic active Epstein-Barr virus infection with reinfection of SARS-CoV-2: a case report

Wu,

Liu,

et al. 2024

Virol J

View full text Add to dashboard Cite

show abstract

“…As with CMV, EBV reactivation has been identified in small subsets of critically ill patients, signifying an additional potential cause of the widespread inflammatory response [135]. Other small retrospective studies and case reports have described increased inflammatory markers in EBV/SARS-CoV-2 co-infection and also reactivation of EBV after SARS-CoV-2 infection that increases risk of death [137][138][139]. Reactivated EBV infection has also been linked to post-acute sequelae of COVID-19 (PASC).…”

Section: Genetic Variants Of Covid-19 Susceptibilitymentioning

confidence: 99%

Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention

Sweet

Freeman

Zidar

2023

PAI

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has had profound effects on the health of individuals and on healthcare systems worldwide. While healthcare workers on the frontlines have fought to quell multiple waves of infection, the efforts of the larger research community have changed the arch of this pandemic as well. This review will focus on biomarker discovery and other efforts to identify features that predict outcomes, and in so doing, identify possible effector and passenger mechanisms of adverse outcomes. Identifying measurable soluble factors, cell-types, and clinical parameters that predict a patient’s disease course will have a legacy for the study of immunologic responses, especially stimuli, which induce an overactive, yet ineffectual immune system. As prognostic biomarkers were identified, some have served to represent pathways of therapeutic interest in clinical trials. The pandemic conditions have created urgency for accelerated target identification and validation. Collectively, these COVID-19 studies of biomarkers, disease outcomes, and therapeutic efficacy have revealed that immunologic systems and responses to stimuli are more heterogeneous than previously assumed. Understanding the genetic and acquired features that mediate divergent immunologic outcomes in response to this global exposure is ongoing and will ultimately improve our preparedness for future pandemics, as well as impact preventive approaches to other immunologic diseases.

show abstract

“…Moreover, we had reported the fatal case of a 70-year-old male patient co-affected by severe COVID-19 and EBV-positive Hodgkin lymphoma [ 51 ]. Other authors have described these associations [ 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ] following COVID-19 vaccination with modRNA and adenoviral vector-based vaccines [ 68 , 69 , 70 , 71 ], which appear worthy of further larger-scale surveys.…”

mentioning

confidence: 99%

SARS-CoV-2 Induced Herpes Virus Reactivations and Related Implications in Oncohematology: When Lymphocytopenia Sets in and Immunosurveillance Drops Out

Roncati,

Sweidan,

Tchawa

et al. 2023

Microorganisms

View full text Add to dashboard Cite

show abstract

Chronic active Epstein-Barr exacerbated by COVID-19 co-infection

Cited by 5 publications

References 14 publications

Chronic active Epstein-Barr virus infection with reinfection of SARS-CoV-2: a case report

Chronic active Epstein-Barr virus infection with reinfection of SARS-CoV-2: a case report

Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and Prevention

SARS-CoV-2 Induced Herpes Virus Reactivations and Related Implications in Oncohematology: When Lymphocytopenia Sets in and Immunosurveillance Drops Out

Contact Info

Product

Resources

About